UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

08 UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

Read More Share:

Dec

04 UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Read More Share:

Dec

03 Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Read More Share:

Nov

14 When Every Second Matters

Read More Share:

Nov

04 Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Read More Share:

Nov

03 U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Read More Share:

Oct

31 Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Read More Share:

Oct

31 BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Read More Share:

Oct

29 UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Read More Share:

Oct

29 UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Read More Share:

Categories

Archives

Dec

08

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

Dec

04

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Dec

03

Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Nov

14

When Every Second Matters

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Dec

08

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

Dec

04

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Dec

03

Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Nov

14

When Every Second Matters

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Oct

31

Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration

Oct

31

BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

Oct

29

UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

Oct

29

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact